MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.

.​https://www.nature.com/articles/d43747-024-00019-5

MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.


​https://www.nature.com/articles/d43747-024-00019-5

Nanoparticles are small particles between 1 nm and 100 nm, and there is growing interest in nanotechnology in energy, electronics, materials science and biomedicine.
The global healthcare nanotechnology market was worth around $320 billion in 2023, and could be worth as much as $894 billion by 2032. Nanoparticles have potential in imaging, diagnostics, bio-implants and tissue engineering. One of their growing roles is in targeted and controlled drug delivery.
​
​Read more at Pharma Sources.

Read the article here.